Quiet ASX debut for BioPharmica
Monday, 09 August, 2004
BioPharmica (ASX: BPH) made its debut on the ASX on Friday afternoon, closing slightly lower than its opening price of AUD$0.25 at $0.21.
The Perth-based company's IPO closed oversubscribed after raising $2.6 million at $0.20 per share in a spin-out from investment company Grandbridge (ASX: GBA), which stands to turn a $1 million profit from the listing.
BioPharmica is developing diagnostic and therapeutic applications for a tumour suppressor gene, HLS5, with a potential role in breast, prostate and colorectal cancers, based on research conducted at the Western Australian Institute of Medical Research.
A second project involves development of genetics-based diagnostic systems for bacterial infections, with an initial focus on diagnosing respiratory tract infections in partnerships with RMIT spin-off, Diagnostic Array Systems.
The company also announced the appointment of US-based consultant Richard O'Connor to its advisory board. Managing Director David Breeze said O'Connor's corporate experience and access to US networks was of the highest calibre.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
